Form 4: Alignment Healthcare CEO Sells Shares Under 10b5-1 Plan

Alignment Healthcare CEO John E. Kao reported the sale of 180,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• John E. Kao, Chief Executive Officer and Director of Alignment Healthcare, Inc. (ALHC), reported the sale of 180,000 shares of common stock.
• The sales occurred on January 12, 2026, and were executed pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2025.
• A total of 177,273 shares were sold at a weighted-average price of $21.0997 per share, with individual transaction prices ranging from $20.48 to $21.47.
• An additional 2,727 shares were sold at a weighted-average price of $21.5665 per share, with individual transaction prices ranging from $21.48 to $21.67.
• Prior to these sales, on January 8, 2026, 665,915 shares directly held by Mr. Kao were transferred to the JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.
• Following these transactions, Mr. Kao beneficially owns 2,832,641 shares indirectly through the JEK Trust and 1,568,379 shares directly, totaling 4,401,020 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the fact that it was conducted under a pre-arranged 10b5-1 plan mitigates concerns that it's based on new, negative non-public information. It's a routine personal financial management action.

Positives

• The reported sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance and not based on new, non-public information.

Negatives

• The CEO reduced his overall beneficial ownership in the company by 180,000 shares through these transactions.

Risks

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence or a desire for diversification by the insider.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction is a routine disclosure for a publicly traded company and does not inherently reflect broader industry trends. It represents a personal financial decision by a key executive, pre-scheduled under a 10b5-1 plan, rather than a strategic corporate move.

Comparison to Industry Standards

• This Form 4 filing reports an insider transaction and does not provide data suitable for comparison to global industry benchmarks, specific comparable companies, projects, or results.

Related Party Transactions

• On January 8, 2026, 665,915 shares directly held by Mr. Kao were transferred to the JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee. This represents a change in the form of beneficial ownership.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO, even under a 10b5-1 plan, slightly reduces insider ownership, which some investors might view as a minor negative. However, the pre-planned nature mitigates concerns about immediate negative implications.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this filing.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company beyond the execution of the pre-planned stock sales.

Key Dates

Recommendation

The insider selling by the CEO, while notable, was conducted under a pre-arranged 10b5-1 plan, which suggests it's a planned personal financial move rather than a reaction to new, adverse company-specific information. This mitigates the negative signal often associated with insider sales. Without additional company-specific financial or operational updates, this filing alone does not warrant a change from a 'hold' position, as it doesn't provide new fundamental insights into the company's performance or prospects.

Keywords

Alignment Healthcare, ALHC, John E. Kao, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Beneficial Ownership